CONMED Corp. 10-Q Summary: Quarter Ended June 30, 2009
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009, for CONMED Corporation, a medical technology company specializing in surgical devices and equipment for minimally invasive procedures. The company operates through five principal units: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec, and CONMED Patient Care. International sales represented approximately 45% of total net sales during the period.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 | Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $164.6 million | $328.6 million |
| Gross Profit | $77.3 million (47.0% margin) | $153.7 million (46.8% margin) |
| Income from Operations | $5.0 million (3.1% margin) | $12.4 million (3.9% margin) |
| Net Income | $1.4 million ($0.05 diluted EPS) | $5.9 million ($0.20 diluted EPS) |
| Cash from Operations | N/A | $14.0 million |
| Total Debt (Current + Long-term) | $186.4 million | $186.4 million |
| Cash and Equivalents | $10.7 million | $10.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 14.6% in the quarter and 14.3% for the six months compared to 2008. This was driven by a 31.3% drop in capital equipment sales and an 8.3% drop in single-use products. Unfavorable foreign currency exchange rates accounted for approximately $9.5 million of the quarterly decline.
- Margin Compression: Gross profit margins decreased 5.3 percentage points to 47.0% in the quarter, primarily due to foreign currency impacts (2.9 points) and restructuring costs (2.2 points).
- Profitability Drop: Net income fell 88% in the quarter and 73% for the six months compared to the prior year periods.
- Restructuring Costs: The company incurred $7.9 million in restructuring costs for the six months ended June 30, 2009, related to facility closures in Utica, NY, and consolidation of distribution centers.
- Debt Repurchase: The company repurchased and retired $9.9 million of its 2.50% convertible senior subordinated notes for $7.8 million, recording a gain of $1.1 million.
Guidance, Outlook, and Risks
- 2009 Outlook: Management expects total revenues for 2009 to decrease 8% to 10% from 2008 levels due to lower sales volumes and unfavorable foreign currency translation.
- Restructuring Plan: The company is executing a plan to close two Utica manufacturing facilities and centralize distribution in Atlanta. Total estimated costs for 2009 are approximately $10.4 million. Completion is expected by the fourth quarter of 2009.
- Pension Plan: Benefit accruals for the U.S. defined benefit pension plan were frozen effective May 14, 2009, resulting in a $4.4 million curtailment gain recorded in the first quarter.
- Subsequent Events: In July 2009, the company announced a plan to consolidate administrative functions of the Endoscopic Technologies division, expecting $3.0 million in charges and $3-$4 million in annual cost savings.
- Risks: Key risks include general economic conditions, foreign exchange volatility, regulatory actions (FDA), and the successful integration of restructuring efforts.
Investor Verification Checklist
- Verify the impact of the strengthening U.S. dollar on future international revenue projections.
- Monitor the execution timeline and cost savings realization of the Utica facility closures and Atlanta distribution consolidation.
- Review the performance of the CONMED Endoscopic Technologies segment, which has historically operated at a loss.
- Assess the adequacy of liquidity given the $14.0 million operating cash flow and $10.7 million cash balance against debt obligations.
- Confirm the status of the pending class-action lawsuit regarding former Linvatec sales representatives (potential exposure up to $3.0 million).